SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 689.27 |
| Enterprise Value ($M) | 654.27 |
| Book Value ($M) | 321.07 |
| Book Value / Share | 12.52 |
| Price / Book | 2.15 |
| NCAV ($M) | 286.41 |
| NCAV / Share | 11.17 |
| Price / NCAV | 2.41 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.20 |
| Return on Assets (ROA) | -0.75 |
| Return on Equity (ROE) | -0.79 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 40.33 |
| Current Ratio | 40.33 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 293.79 |
| Assets | 328.45 |
| Liabilities | 7.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 9.90 | 24.15 | |
| 13G | Avoro Capital Advisors LLC | 8.70 | ||
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G/A | Viking Global Investors Lp | 0.00 | ||
| 13G/A | Blue Owl Capital Holdings LP | 6.00 | 14.87 | |
| 13G | BlackRock, Inc. | 6.80 | 0.00 | |
| 13G/A | Pfizer Inc | 4.96 | ||
| 13G/A | Hydra LLC | 6.60 | 41.59 | |
| 13G/A | Citadel Advisors Llc | 0.00 | ||
| 13G/A | Blackstone Holdings II L.P. | 0.00 | ||
| 13G | TCG Crossover GP I, LLC | 5.90 | ||
| 13G/A | BML Investment Partners, L.P. | 1.00 | ||
| 13D/A | Qiming U.S. Healthcare GP II, LLC | 3.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 30,081 | 148,679 | 20.23 | |
| 26,290 | 158,684 | 16.57 | |
| 19,615 | 149,082 | 13.16 | |
| 88,845 | 320,738 | 27.70 | |
| 31,498 | 154,705 | 20.36 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TERN – Terns Pharmaceuticals, Inc. | TLRY – Tilray Brands, Inc. |
| TNYA – Tenaya Therapeutics, Inc. | TSHA – Taysha Gene Therapies, Inc. |
| TSVT – 2seventy bio, Inc. |
Financial data and stock pages provided by
Fintel.io